Merck & Co. Inc., of Kenilworth, N.J., reported fourth-quarter and full-year sales of PD-1 inhibitor Keytruda (pembrolizumab) of $1.297 billion and $3.809 billion, respectively. Read More

TG Therapeutics Inc., of New York, reported results from its ongoing phase II trial testing ublituximab (TG-1101), a glycoengineered anti-CD20 monoclonal antibody, in patients with the relapsing forms of multiple sclerosis (RMS) at the 3rd Annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2018 in San Diego. Read More

Canbridge Life Sciences Inc., of Beijing, said it has licensed the exclusive rights to develop and commercialize Nerlynx (neratinib) in China, Taiwan, Hong Kong and Macao (collectively, greater China) from Puma Biotechnology Inc., of Los Angeles. Read More

Seattle Genetics Inc., of Bothell, Wash., said the underwriters exercised their option to purchase an additional 1.7 million shares in its previously announced offering, bringing the total shares offered to about 13.3 million at a price of $52 per share. Read More

The results are in from the first long-running, randomized study to assess the relative benefits of catheter ablation vs. drug therapy to treat patients with heart failure and atrial fibrillation. The data in the eight-year trial show that ablation roundly bests drug treatment in the prevention of death, stroke and hospitalization. Read More

Like many others – except, as usual, for significantly more money – Moderna Therapeutics Inc. took advantage of a generous market to raise $500 million from new U.S. and international institutional investors, as well as institutional supporters already on board. Read More

Amgen Inc. shares (NASDAQ:AMGN), dented by missed fourth-quarter earnings expectations, regained lost ground Friday, buoyed by expectations for a lower 2018 tax rate and its plans to repurchase up to $10 billion of its own shares through a Dutch auction, starting as early as this week. Read More

By comparing the proteomes of affected and unaffected family members, researchers have gained new insights into the rare genetic disorder Menkes disease, and found that it has molecular connections to Parkinson's disease (PD). Read More

Data from the phase II SUMMIT basket trial of HER tyrosine kinase inhibitor neratinib (Puma Biotechnology Inc.) in patients with HER2 or HER3-mutated tumors across multiple anatomical locations have shown that targeting HER2 can have therapeutic value in tumors beyond breast cancer, but also reaffirmed that for most targeted therapies, the anatomical location as well as the molecular mutation play a role. Read More